Symmonds J, Gaufin T, Xu C, Raehtz K, Ribeiro R, Pandrea I
Viruses. 2024; 16(6.
PMID: 38932264
PMC: 11209256.
DOI: 10.3390/v16060972.
Perez P, Marin M, Lazaro-Frias A, Sorzano C, Gomez C, Esteban M
Vaccines (Basel). 2020; 8(1).
PMID: 32041218
PMC: 7158668.
DOI: 10.3390/vaccines8010070.
Perez P, Marin M, Lazaro-Frias A, Sorzano C, Di Pilato M, Gomez C
Vaccines (Basel). 2019; 7(4).
PMID: 31817622
PMC: 6963416.
DOI: 10.3390/vaccines7040208.
Cardozo E, Apetrei C, Pandrea I, Ribeiro R
Immunol Rev. 2018; 285(1):26-37.
PMID: 30129200
PMC: 6352983.
DOI: 10.1111/imr.12691.
Iyer S, Amara R
Vaccines (Basel). 2015; 2(1):160-78.
PMID: 26344473
PMC: 4494194.
DOI: 10.3390/vaccines2010160.
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?.
Vanham G, Van Gulck E
Retrovirology. 2012; 9:72.
PMID: 22958464
PMC: 3472319.
DOI: 10.1186/1742-4690-9-72.
Immune modulation through 4-1BB enhances SIV vaccine protection in non-human primates against SIVmac251 challenge.
Hirao L, Hokey D, Morrow M, Jure-Kunkel M, Weiner D
PLoS One. 2011; 6(9):e24250.
PMID: 21935390
PMC: 3174159.
DOI: 10.1371/journal.pone.0024250.
A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses.
Garcia-Arriaza J, Najera J, Gomez C, Tewabe N, Sorzano C, Calandra T
PLoS One. 2011; 6(8):e24244.
PMID: 21909386
PMC: 3164197.
DOI: 10.1371/journal.pone.0024244.
Immunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions.
Garcia-Arriaza J, Najera J, Gomez C, Sorzano C, Esteban M
PLoS One. 2010; 5(8):e12395.
PMID: 20811493
PMC: 2927552.
DOI: 10.1371/journal.pone.0012395.
Experimental depletion of CD8+ cells in acutely SIVagm-infected African Green Monkeys results in increased viral replication.
Gaufin T, Ribeiro R, Gautam R, Dufour J, Mandell D, Apetrei C
Retrovirology. 2010; 7:42.
PMID: 20459829
PMC: 2879233.
DOI: 10.1186/1742-4690-7-42.
Recombinant Mycobacterium bovis BCG as an HIV vaccine vector.
Chapman R, Chege G, Shephard E, Stutz H, Williamson A
Curr HIV Res. 2010; 8(4):282-98.
PMID: 20353397
PMC: 3188323.
DOI: 10.2174/157016210791208686.
HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers.
Cheroutre H
F1000 Biol Rep. 2010; 1:89.
PMID: 20046812
PMC: 2799925.
DOI: 10.3410/B1-89.
CD8+ cell depletion of SHIV89.6P-infected macaques induces CD4+ T cell proliferation that contributes to increased viral loads.
Mueller Y, Do D, Boyer J, Kader M, Mattapallil J, Lewis M
J Immunol. 2009; 183(8):5006-12.
PMID: 19786539
PMC: 2757467.
DOI: 10.4049/jimmunol.0900141.
Improved survival in rhesus macaques immunized with modified vaccinia virus Ankara recombinants expressing simian immunodeficiency virus envelope correlates with reduction in memory CD4+ T-cell loss and higher titers of neutralizing antibody.
Ourmanov I, Kuwata T, Goeken R, Goldstein S, Iyengar R, Buckler-White A
J Virol. 2009; 83(11):5388-400.
PMID: 19321617
PMC: 2681965.
DOI: 10.1128/JVI.02598-08.
Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens.
Mooij P, Balla-Jhagjhoorsingh S, Beenhakker N, van Haaften P, Baak I, Nieuwenhuis I
J Virol. 2009; 83(11):5881-9.
PMID: 19321612
PMC: 2681993.
DOI: 10.1128/JVI.02345-08.
Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge.
Schell J, Rose N, Fazo N, Marx P, Hunter M, Ramsburg E
Vaccine. 2009; 27(7):979-86.
PMID: 19135115
PMC: 2661574.
DOI: 10.1016/j.vaccine.2008.12.017.
Increased loss of CCR5+ CD45RA- CD4+ T cells in CD8+ lymphocyte-depleted Simian immunodeficiency virus-infected rhesus monkeys.
Veazey R, Acierno P, McEvers K, Baumeister S, Foster G, Rett M
J Virol. 2008; 82(11):5618-30.
PMID: 18367534
PMC: 2395171.
DOI: 10.1128/JVI.02748-07.
Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques.
Sadagopal S, Amara R, Kannanganat S, Sharma S, Chennareddi L, Robinson H
J Virol. 2008; 82(8):4149-53.
PMID: 18234787
PMC: 2292989.
DOI: 10.1128/JVI.02242-07.
Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates.
Mooij P, Balla-Jhagjhoorsingh S, Koopman G, Beenhakker N, van Haaften P, Baak I
J Virol. 2008; 82(6):2975-88.
PMID: 18184713
PMC: 2258966.
DOI: 10.1128/JVI.02216-07.
Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses.
Li Y, Cleveland B, Klots I, Travis B, Richardson B, Anderson D
J Virol. 2007; 82(2):638-51.
PMID: 17959660
PMC: 2224603.
DOI: 10.1128/JVI.01691-07.